Marinus Pharmaceuticals Inc. (MRNS)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XFRA 
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNS
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors who lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact Levi & Korsinsky about pending Class Action - MRNS
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
MRNS SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
Investors who lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact Levi & Korsinsky about pending Class Action - MRNS
NEW YORK, NY / ACCESSWIRE / July 13, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Initiates An Inquiry Into Marinus Pharmaceuticals Inc And Urges Impacted Investors To Start Conversation
LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Notifies Shareholders of Marinus Pharmaceuticals, Inc.(MRNS) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
MRNS SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 5, 2024 in Marinus Lawsuit - MRNS
NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Starts An Investigation Into Marinus Pharmaceuticals Inc And Encourages Affected Investors To Begin Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders of Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
